Core Viewpoint - Tevogen Bio Holdings Inc. has announced the publication of its international patent application for a machine learning-based technology aimed at identifying immunologically active peptides, which is crucial for developing targeted therapies for diseases like cancer and infections [1][2]. Group 1: Technology and Innovation - The patented technology utilizes machine learning algorithms, developed in collaboration with Microsoft and Databricks, to enhance the identification of peptides that interact strongly with the immune system [1]. - Traditional methods for identifying these peptides often overlook important genetic diversity factors, but Tevogen.AI's approach aims to address these limitations [2]. - The technology focuses on efficiently screening and ranking potential peptides based on their immunological activity and continuously refining predictions using real-world data [6]. Group 2: Strategic Goals - The company emphasizes the importance of leveraging artificial intelligence to accelerate discovery, shorten development timelines, and reduce costs in the context of personalized T cell therapies [2]. - The goal is to deliver commercially attractive and economically viable therapies for various diseases, including cancers and infectious diseases [2].